Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
OBJECTIVE
To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH).


METHODS
The subjects were patients who had LUTS and BPH. They were treated with terazosin (1 mg, twice-a-day) for 12 weeks. Calculation of the International Prostate Symptom Score (IPSS), measurement of blood pressure, and uroflowmetry were performed before and after 12 weeks of therapy. Patients were divided into a normotensive (NT) group and a hypertensive (HT) group at the time of first examination.


RESULTS
The IPSS for urinary frequency and nocturia in BPH-HT patients (n = 21; mean age, 71 years) were significantly higher than those in the BPH-NT patients (n = 21; mean age, 69 years) before the administration of terazosin. The total IPSS the BPH-HT patients was also significantly higher than that of the BPH-NT patients. There were no differences of uroflowmetric parameters between the two groups. After 12 weeks of therapy, systolic and diastolic blood pressure decreased in the BPH-HT patients, but not in the BPH-NT patients. However, the systolic pressure of the BPH-HT patients was still significantly higher than that of the BPH-NT patients. The score for each IPSS parameter decreased in both groups, but the difference of the score between the two groups increased.


CONCLUSIONS
Hypertension may worsen LUTS and may decrease the improvement of symptoms by terazosin.
Sugaya
Kimio
K
Department of Urology, Faculty of Medicine, University of the Ryukyus, Uehara, Nishihara, Okinawa, Japan. sugaya@med.u-ryukyu.ac.jp
Kadekawa
Katsumi
K
Ikehara
Akashi
A
Nakayama
Tomoyuki
T
Gakiya
Munehisa
M
Nashiro
Fumio
F
Goya
Masato
M
Hatano
Tadashi
T
Ogawa
Yoshihide
Y
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D008297:Male; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000150:complications*; D012016:Reference Values; D016896:Treatment Outcome; D014555:Urination Disorders / Q000209:etiology* / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin